CAGR: 6.9%Current Market Size: 7.83 Billion Fastest Growing Region: APAC
Largest Market: North AmericaProjection Time: 2022-2029Base Year: 2021
The global Real-time PCR, Digital PCR, and End-point PCR market are expected to grow from USD 7.83 billion in 2021 to USD 13.09 billion by 2029, at a CAGR of 6.9% during the Projection period 2022-2029. The prevalence of infectious & genetic diseases, technological innovations in PCR, and the COVID-19 pandemic have driven the growth of the global market.
Polymerase chain reaction (PCR) is a laboratory technique mainly used to produce millions to billions of copies of a specific segment of DNA. In addition, it is a highly accurate and fast way to diagnose genetic changes and infectious diseases. Real-time PCR, Digital PCR, and End-point PCR are the technologies used in PCR for specific quantification and detection of nucleic acids. The researchers interested in quantifying and detecting nucleic acids can use next-generation DNA sequencing; however, they often turn to some form of PCR, either digital PCR (dPCR) or real-time quantitative PCR (qPCR).
Real-time PCR, Digital PCR, and End-point PCR all include similar reaction dynamics, but the analysis process of PCR products is different. Among these technologies, endpoint PCR is used in applications such as sequencing, cloning, genotyping, and sequence detection.
Request Sample: - Global Real-time PCR, Digital PCR, and End-point PCR Market
Market Dynamics:
Drivers:
PCR tests have become essential for treating infectious & genetic diseases due to their fast and highly accurate way of diagnosing diseases. For instance, these tests are preferred to analyze clinical specimens for the detecting presence of infectious agents, such as HIV, human papillomavirus, Epstein-Barr virus, hepatitis, malaria, and anthrax.
Moreover, the ongoing development of technologically advanced infectious disease test kits further boosts the market's growth. For instance, in December 2021, Roche, a Swiss multinational healthcare company, launched the first infectious disease test on the Cobas 5800 System, an innovative molecular laboratory instrument. This system includes Cobas HBV, a real-time PCR test.
PCR technologies revolutionized molecular biology and enabled clinicians to diagnose genetic disorders and infectious diseases. In addition, new advances in PCR technology, such as high-throughput instruments and more sensitive assays, have further revolutionized healthcare by allowing routine blood tests for early cancer detection.
Moreover, automation of different aspects of the PCR assay, including microfluidics, robotics, and nanotechnology, has led to the rapid advancement of new procedures. For instance, the procedures, including Real-time PCR, DNA chips, and DNA microarray, use automated technologies in combination with computer & computer programs. The advances mentioned above in PCR technologies have driven the market's growth.
Restraints:
Digital PCR assays, instruments, and kits offer high sensitivity and accuracy. However, it suffers from a higher cost of production, which hampers its large-scale manufacturing. On the other hand, a basic PCR machine costs around $5,000, while top-of-the-line qPCR or RT-PCR systems ranges from $15,000 to over $90,000. In molecular biology, such high costs make PCR systems inaccessible for facilities with a limited budget. Hence, the high costs associated with Digital PCR hamper the market's growth to some extent.
Opportunities:
The rising prevalence of chronic and infectious diseases, along with increasing R&D investment for developing innovative genomic techniques, has boosted demand for Real-time PCR, Digital PCR, and End-point PCR in emerging countries. In addition, developing countries such as China, India, and Brazil are seeing a rapid expansion of healthcare infrastructure. Moreover, there is a trend of declining procedural costs associated with dPCR-based and qPCR-based disease diagnoses. Such factors are opportunistic for the growth of the global market.
Challenges
MIQE is a set of guidelines regarding the minimum information required to evaluate qPCR experiments. However, there are several challenges to meeting these guidelines. For instance, researchers need to be able to demonstrate that their investigation has been undertaken correctly. Also, they should present all of the additional relevant data. Moreover, these guidelines require researchers to demonstrate that the instrument being used is up to the necessary standard.
Segmentation Analysis:
The global Real-time PCR, Digital PCR, And End-point PCR market have been segmented based on technology, product, end user, and regions.
By Technology
The technology segment includes quantitative, digital, and End-point. The quantitative PCR segment led the Real-time PCR, Digital PCR, And End-point PCR market with a market share of around 81.6% in 2021. This is mainly due to technological advancements and increased demand for automated systems. In addition, real-time quantitative PCR (RT-qPCR) technology has significantly revolutionized every area of molecular biology in the past few years. In addition, this technology is being utilized for mainstream testing across regulated markets such as veterinary, food, and human in-vitro diagnostics.
By Product
The product segment includes consumables & reagents, instruments, and software & services. The consumables & reagents segment led the Real-time PCR, Digital PCR, And End-point PCR market with a market share of around 61.40% in 2021. Growing demand for earlier detection of diseases, an outbreak of the COVID-19 pandemic, and an upsurge in the development of digital PCR reagents and consumables have mainly driven the growth of this segment. For instance, in December 2020, Stilla Technologies, a European provider high–precision genetic analysis solutions, introduced a dedicated digital PCR MIX reagent line for optimal performance with Crystal Digital PCR. The new reagents offered by Stilla Technologies are ready-to-use solutions mainly optimized for the robustness and performance of digital PCR applications.
By End User
The end user segment includes clinical, research, and forensic. The clinical segment led the Real-time PCR, Digital PCR, And End-point PCR market with a market share of around 81.3% in 2021. This is attributed to the commercialization of reagents for diagnostics and the prevalence of diseases, including cancer, diabetes, and infectious diseases. For instance, PCR technologies have significantly revolutionized the diagnosis of lymphomas, leukemias, and solid tumors over the past years. In addition, it has enabled the diagnosis of infectious microbes causing maxillofacial infections.
By Regional Analysis:
The regions analyzed for the Real-time PCR, Digital PCR, And End-point PCR market include North America, Europe, South America, Asia Pacific, and the Middle East, and Africa. The North American region dominated the Real-time PCR, Digital PCR, And End-point PCR market and held the 36.21% share of the market revenue in 2021.
Global Real-time PCR, Digital PCR, and End-point PCR Market- Country Analysis:
In Europe, Germany is one of the largest market shareholders in the Real-time PCR, Digital PCR, and End-point PCR market. In addition, this country has a strong healthcare system, especially regarding hospital beds, infrastructure, equipment, and trained staff. These factors have primarily driven the growth of the market.
Germany's Real-time PCR, Digital PCR, And End-point PCR market size was valued at USD 0.86 billion in 2021 and is expected to reach USD 1.42 billion by 2029, at a CAGR of 6.7% from 2022 to 2029.
Further, an outbreak of the COVID-19 pandemic has boosted the demand for PCR technologies in Germany. For instance, in January 2021, ERBA Mannheim, the biotechnology company in Mannheim, Germany, launched the ErbaMDx SARS-CoV-2 RT-PCR Kit to detect SARS-CoV-2.
China's Real-time PCR, Digital PCR, and End-point PCR market size was valued at USD 1.57 billion in 2021 and is expected to reach USD 2.56 billion by 2029, at a CAGR of 6.6% from 2022 to 2029. China is a prominent Real-time PCR, Digital PCR, and End-point PCR market due to economic growth, government initiatives, aging population, and expanding health care sector. In addition, according to the Ministry of Industry & Information Technology of China (MIIT), the medical equipment market in China was expected to grow at a CAGR of 15% between 2021 and 2015. On the other hand, the government of China has planned an expansive healthcare ecosystem of about 16 trillion RMB by the end of the decade with continuous optimization of healthcare management & services. Such factors have altogether fueled China's Real-time PCR, Digital PCR, and End-point PCR market.
India's Real-time PCR, Digital PCR, And End-point PCR market size was valued at USD 0.39 billion in 2021 and is expected to reach USD 0.66 billion by 2029, at a CAGR of 7.1% from 2022 to 2029. India is one of the highest growing economies in Asia. In addition, this country is seeing increased government spending on developing healthcare facilities. For instance, according to the Deccan Herald, an Indian English language daily newspaper, the Covid-19 pandemic has increased India's health expenditure to 2.1% of GDP.
Moreover, in May 2022, Cipla Limited, an Indian multinational pharmaceutical company, announced the commercialization of its real-time COVID-19 RT-PCR test kit across India. This trend of PCR test kit commercialization in the country creates lucrative growth opportunities for the market.
Key Industry Players Analysis:
To increase their market position in the global Real-time PCR, Digital PCR, and End-point PCR business, top companies are focusing on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, and partnerships, joint ventures, etc.
Latest Development:
Report Metrics
Report Attribute |
Details |
Study Period |
2021-2029 |
Base year |
2021 |
CAGR (%) |
6.9% |
Market Size |
7.83 billion in 2021 |
Projection period |
2022-2029 |
Projection unit |
Value (USD) |
Segments covered |
Product, application, end user , and Regions |
Report Scope |
Revenue Projection, competitive landscape, company ranking, growth factors, and trends |
Companies covered |
Abbott, Qiagen, Bio-Rad Laboratories Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., GE Healthcare, BIOMÉRIEUX, F. Hoffmann-La Roche Ltd., Fluidigm Corporation, and Danaher Corporation among others |
By Technology |
|
By Product |
|
By End User |
|
Regional scope |
|
Scope of the Report
Global Real-time PCR, Digital PCR, and End-point PCR Market by Technology:
Global Real-time PCR, Digital PCR, and End-point PCR Market by Product:
Global Real-time PCR, Digital PCR, and End-point PCR Market by End User:
Global Real-time PCR, Digital PCR, and End-point PCR Market by Region:
The market size of global Real-time PCR, Digital PCR, and End-point PCR market are expected to grow from USD 7.83 billion in 2021.
Growth rate of Global Real-time PCR, Digital PCR, and End-point PCR market CAGR of 6.9% from 2022 to 2029 and it will reach to USD 13.09 billion by 2029
The global Real-time PCR, Digital PCR, and End-point PCR market have been segmented based on technology, product, end user, and regions.
Leading market players active in the global Real-time PCR, Digital PCR, and End-point PCR market are Abbott, Qiagen, Bio-Rad Laboratories Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., GE Healthcare, BIOMÉRIEUX, F. Hoffmann-La Roche Ltd., Fluidigm Corporation, and Danaher Corporation among others.
MIQE is a set of guidelines regarding the minimum information required to evaluate qPCR experiments. However, there are several challenges to meeting these guidelines. For instance, researchers need to be able to demonstrate that their investigation has been undertaken correctly.
In By-Product consumables & reagents segment led the Real-time PCR, Digital PCR, And End-point PCR market with a market share of around 61.40% in 2021
Political Factors- The U.S. FDA approved Emergency Use Authorization (EUA) for Bio-Rad’s SARS-CoV-2 ddPCR Kit to detect SARS-CoV-2 infection. In addition, regulatory agencies have expressed strong support for approving these tests to mitigate the impact of the COVID-19 outbreak. MIQE is a set of guidelines regarding the minimum information required to evaluate qPCR experiments. However, there are several challenges to meeting these guidelines. For instance, researchers need to be able to demonstrate that their investigation has been undertaken correctly. Also, they should present all of the additional relevant data. Moreover, these guidelines require researchers to demonstrate that the instrument being used is up to the necessary standard.
Economical Factors- Digital PCR assays, instruments, and kits offer high sensitivity and accuracy. However, it suffers from a higher cost of production, which hampers its large-scale manufacturing. On the other hand, a basic PCR machine costs around $5,000, while top-of-the-line qPCR or RT-PCR systems ranges from $15,000 to over $90,000. In molecular biology, such high costs make PCR systems inaccessible for facilities with a limited budget. Hence, the high costs associated with Digital PCR hamper the market's growth to some extent. On the other hand, the government of China has planned an expansive healthcare ecosystem of about 16 trillion RMB by the end of the decade with continuous optimization of healthcare management & services.
Social Factor- Upsurge in the number of hospitals, increasing healthcare spending, and improved healthcare infrastructure has driven the growth of the Asia-Pacific Real-time PCR, Digital PCR, and End-point PCR market. Moreover, clinical development frameworks in developing economies such as Australia and India are opportunistic for market growth. On the other hand, Germany has a strong healthcare system, especially regarding hospital beds, infrastructure, equipment, and trained staff. These factors have primarily driven the growth of the market.
Technological Factors- PCR technologies revolutionized molecular biology and enabled clinicians to diagnose genetic disorders and infectious diseases. In addition, new advances in PCR technology, such as high-throughput instruments and more sensitive assays, have further revolutionized healthcare by allowing routine blood tests for early cancer detection. Moreover, automation of different aspects of the PCR assay, including microfluidics, robotics, and nanotechnology, has led to the rapid advancement of new procedures. For instance, the procedures, including Real-time PCR, DNA chips, and DNA microarray, use automated technologies in combination with computer & computer programs. The advances mentioned above in PCR technologies have driven the market's growth.
Environmental Factors- According to various studies, it has been found that the production of several manufacturing processes and excessive use of chemicals harms the environment and causes pollution. In addition, several factors add to the increasing global warming, which causes an increase in temperature every year, and the weather condition changes leading to extremes in each weather. This may be further responsible for biodiversity loss and deforestation. Hence, the aforementioned environmental concerns triggered by the use of excessive medical equipment and products may pose significant challenges to the environment.
Legal Factors- Qiagen NV announced a collaboration with Atila BioSystems, a biological and chemical engineering company, to provide non-invasive prenatal testing (NIPT) solutions to the dPCR franchise of Qiagen. Cipla Limited, an Indian multinational pharmaceutical company, announced the commercialization of its real-time COVID-19 RT-PCR test kit across India. This trend of PCR test kit commercialization in the country creates lucrative growth opportunities for the market. Thermo Fisher Scientific Inc., an American supplier of scientific instrumentation, consumables, and reagents, launched the fully integrated digital PCR (dPCR) system. This dPCR offers consistent and extremely accurate results within 90 minutes.
List of Table
List of Figures